Calcified Tissue International

, Volume 86, Issue 5, pp 404–410 | Cite as

Autocrine/Paracrine Action of Vitamin D on FGF23 Expression in Cultured Rat Osteoblasts

  • Wen-Jing Tang
  • Li-Fang Wang
  • Xiao-Ya Xu
  • Yi Zhou
  • Wei-Fang Jin
  • Hong-Fu Wang
  • Jianjun Gao


To explore the local mechanisms of fibroblast growth factor (FGF) 23 regulations, we examined the FGF23 expression patterns in an osteoblast culture model. The characteristics of cultured rat calvaria osteoblasts in half-confluence, confluence, osteoid deposition, and osteoid mineralization stages might reflect the proliferation, differentiation, maturation, and matrix mineralization stages, respectively. Compared with proliferating cells in half-confluence, FGF23 expression was upregulated by 7.5-fold at the mRNA level and 126% at the protein level in confluent differentiated cells as determined by real-time RT-PCR and Western blot analysis. Interestingly, mRNA levels of CYP27B1 (the gene coding for 1α-hydroxylase enzyme which catalyses the conversion of 1α,25-dihydroxyvitamin D, 1α,25[OH]2D, from its inactive form, 25-hydroxycholecalciferol, 25[OH]D) and CYP24A (the gene coding for 24-hydroxylase, a target gene of 1α,25[OH]2D) were significantly increased by twofold and 34-fold, respectively, in differentiated osteoblasts compared with proliferating cells. We next examined if the local production of 1α,25(OH)2D might contribute to the FGF23 upregulation. We cultured osteoblasts in serum-free medium with or without 25-(OH)D (the substrate of 1α-hydroxylase). FGF23 mRNA levels were increased in proliferating cells (16-fold) and in differentiated cells (28-fold) by the physiological dose of 25-(OH)D3 treatment. CYP27B1 was slightly but significantly upregulated and CYP24A was increased by 1,700-fold and 800-fold, respectively, in transcriptional levels. Because FGF23 was upregulated in confluent osteoblasts regardless of the presence or absence of 25-(OH)D in serum-free medium, we further examined the possible impact of cell communication on FGF23 expression. We treated osteoblasts with carbenoxolone, a gap junction Cx43 blocker in serum-free medium. The FGF23 mRNA level was reduced by 50% in confluent differentiated cells and slightly but not significantly reduced in half-confluent cells by carbenoxolone treatments. The results suggested that upregulation of FGF23 in differentiated osteoblast appeared to be due to increased autocrine/paracrine action of osteoblast-derived 1α,25(OH)2D and increased cell communication, which were identified in cultured rat calvaria osteoblasts. These results indicate that FGF23 expression was stimulated not only by circulating calcitriol but also by locally produced 1α,25(OH)2D. The local mechanisms of FGF23 expression remain to be characterized.


Rat osteoblast Fibroblast growth factor 23 1α,25-Dihydroxyvitamin D Gap junction 


  1. 1.
    Shimada T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505CrossRefPubMedGoogle Scholar
  2. 2.
    Consortium ADHR (2000) Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRefGoogle Scholar
  3. 3.
    Quarles LD (2003) Evidence for a bone–kidney axis regulating phosphate homeostasis. J Clin Invest 112:642–646PubMedGoogle Scholar
  4. 4.
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663CrossRefPubMedGoogle Scholar
  5. 5.
    White KE, Econs MJ (2008) Fibroblast growth factor-23. In: Rosen CJ (ed) Primer on the metabolic bone disease and disorders of mineral metabolism, 7th edn. American Society for Bone and Mineral Research, Washington DC, pp 112–116Google Scholar
  6. 6.
    Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315CrossRefPubMedGoogle Scholar
  7. 7.
    Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro OM, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003–4008PubMedGoogle Scholar
  8. 8.
    Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125–131CrossRefPubMedGoogle Scholar
  9. 9.
    Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maedaet N (2007) Mineralized tissue cells are a principal source of FGF23. Bone 40:1565–1573CrossRefPubMedGoogle Scholar
  10. 10.
    Martin A, Quarles LD (2009) The actors in phosphate metabolism and bone mineral homeostasis: meeting report from the 31st annual meeting of the American Society for Bone and Mineral Research. IBMS BoneKEy 6:455–458CrossRefGoogle Scholar
  11. 11.
    Bellows CG, Aubin JE, Heersche JN, Antosz ME (1986) Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 38:143–154CrossRefPubMedGoogle Scholar
  12. 12.
    Aubin JE, Lain JB, Stein GS (2006) Bone formation: maturation and functional activities of osteoblast lineage cells. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. American Society for Bone and Mineral Research, Washington DC, pp 20–29Google Scholar
  13. 13.
    Wang H-F, Jin W-F, Gao J-J (2001) Osteoblast culture techniques in vitro. In: Wang H-F (ed) An atlas of bone cells & cell culture techniques. Shanghai Scientific & Technical Publishers, Shanghai, pp 54–55Google Scholar
  14. 14.
    Wang H-F, Jin W-F, Gao J-J, Sheng H (2008) Osteoblast culture and pharmacological evaluation in vitro. In: Leung KS, Qin YX, Cheung WH, Qin L (eds) A practical manual for musculoskeletal research. World Scientific, Singapore, pp 99–112CrossRefGoogle Scholar
  15. 15.
    Gao J, Tiwari-Pandey R, Samadfam R, Yang Y, Miao D, Karaplis AC, Sairam MR, Goltzman D (2007) Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone (FSH). Endocrinology 148:2613–2621CrossRefPubMedGoogle Scholar
  16. 16.
    Anderson PH, O’Loughlin PD, Maya BK, Morris HA (2005) Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 36:654–662CrossRefPubMedGoogle Scholar
  17. 17.
    Howard GA, Turner RT, Sherrard DJ, Baylink DJ (1981) Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J Biol Chem 256:7738–7740PubMedGoogle Scholar
  18. 18.
    Ichikawa F, Sato K, Nanjo M, Nishii Y, Shinki T, Takahashi N, Suda T (1995) Mouse primary osteoblasts express vitamin D3 25-hydroxylase mRNA and convert 1α-hydroxyvitamin D3 into 1α,25-dihydroxyvitamin D3. Bone 16:129–135CrossRefPubMedGoogle Scholar
  19. 19.
    van Driel M, Koedam M, Buurman CJ, Hewison M, Chiba H, Uitterlinden AG, Pols HA, van Leeuwen JP (2006) Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 20:2417–2419CrossRefPubMedGoogle Scholar
  20. 20.
    Kemmis CM, Salvador SM, Smith KM, Welsh J (2006) Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D3, the major circulating form of vitamin D3. J Nutr 136:887–892PubMedGoogle Scholar
  21. 21.
    Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zannettino ACW, O’Loughlin PD, Morris HA (2007) Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D3. Bone 40:1517–1528CrossRefPubMedGoogle Scholar
  22. 22.
    Anderson PH, Atkins GJ, Findlay DM, Oloughlin PD, Welldon K, Vincent C, Morris HA (2007) RNAi-mediated silencing of CYP27B1 abolishes 1,25(OH)2D3 synthesis and reduces osteocalcin and CYP24 mRNA expression in human osteosarcoma (HOS) cells. J Steroid Biochem Mol Biol 103:601–605CrossRefPubMedGoogle Scholar
  23. 23.
    Anderson PH, Sawyer RK, Moore AJ, May BK, O’Loughlin PD, Morris HA (2008) Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res 23:1789–1797CrossRefPubMedGoogle Scholar
  24. 24.
    Lecanda F, Warlow PM, Sheikh S, Furlan F, Steinberg TH, Civitelli R (2000) Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol 151:931–944CrossRefPubMedGoogle Scholar
  25. 25.
    Chung DJ, Castro CH, Watkins M, Stains JP, Chung MY, Szejnfeld VL, Willecke K, Theis M, Civitelli R (2006) Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci 119:4187–4198CrossRefPubMedGoogle Scholar
  26. 26.
    McLachlan E, Plante I, Shao Q, Tong D, Kidder GM, Bernier SM, Laird DW (2008) ODDD-linked Cx43 mutants reduce endogenous Cx43 expression and function in osteoblasts and inhibit late stage differentiation. J Bone Miner Res 23:928–938CrossRefPubMedGoogle Scholar
  27. 27.
    Saez JCT, Retamal MA, Basilio D, Bukauskas FF, Bennett MVL (2005) Connexin-based gap junction hemichannels: gating mechanisms. Biochim Biophys Acta 1711:215–224CrossRefPubMedGoogle Scholar
  28. 28.
    Masuyama R, Stockmans I, Torrekens S, Looveren RV, Maes C, Carmelie P, Bouillon R, Carmeliet G (2006) Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 116:3150–3159CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Wen-Jing Tang
    • 1
  • Li-Fang Wang
    • 1
  • Xiao-Ya Xu
    • 1
  • Yi Zhou
    • 2
  • Wei-Fang Jin
    • 2
  • Hong-Fu Wang
    • 2
  • Jianjun Gao
    • 3
  1. 1.Department of Bone Metabolism, Institute of Radiation MedicineFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Bone Metabolism, Institute of Radiation MedicineFudan UniversityShanghaiPeople’s Republic of China
  3. 3.Department of Bone Metabolism, Institute of Radiation MedicineFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations